Top publications
- Gómez, V., M. Galazi, G. Weitsman, J. Monypenny, F. Al-Salemee, P. R. Barber, K. Ng, R. Beatson, B. Szokol, L. Őrfi, G. Mullen, B. Vanhaesebroeck, S. Chowdhury, H. Y. Leung and T. Ng
HER2 mediates PSMA/mGluR1-driven resistance to the DS-7423 dual PI3K/mTOR inhibitor in PTEN wild-type prostate cancer models
MOLECULAR CANCER THERAPEUTICS molcanther.0320.2021 (2022)
- Veres-Székely, A., D. Pap, B. Szebeni, L. Őrfi, C. Szász, C. Pajtók, E. Lévai, A. J. Szabó and Á. Vannay
Transient Agarose Spot (TAS) Assay: A New Method to Investigate Cell Migration
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 23(4). (2022)
- Nelhűbel, G., M. Cserepes, B. Szabó, D. Türk, A. Kárpáti, I. Kenessey, E. Rásó, T. Barbai, Z. Hegedűs, V. László, B. Szokol, J. Dobos, L. Őrfi and J. Tóvári
EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas
PATHOLOGY AND ONCOLOGY RESEARCH 27. (2021)
- Bencze, G., S. Bencze, K. D. Rivera, J. D. Watson, M. Hidvegi, L. Orfi, N. K. Tonks and D. J. Pappin
Mito-oncology agent: fermented extract suppresses the Warburg effect, restores oxidative mitochondrial activity, and inhibits in vivo tumor growth
SCIENTIFIC REPORTS 10(1): 14174. (2020)
- Baska, F., A. Sipos, Z. Őrfi, Z. Nemes, J. Dobos, C. Szántai-Kis, E. Szabó, G. Szénási, L. Dézsi, P. Hamar, M. T. Cserepes, J. Tóvári, R. Garamvölgyi, M. Krekó and L. Őrfi
Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 184: 111710. (2019)
- Kiss E, Mirzahosseini A, Hubert Á, Ambrus A, Őrfi L, Horváth P
DNA binding of sunitinib: Spectroscopic evidence via circular dichroism and nuclear magnetic resonance
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 150: pp. 355-361. (2018)
- Nemes Z, Takács-Novák K, Völgyi G, Valko K, Béni S, Horváth Z, Szokol B, Breza N, Dobos J,
Szántai-Kis C, Illyés E, Boros S, Kok RJ, Őrfi L
Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 28:(14) pp. 2391-2398. (2018)
- Gyulavári P, Szokol B, Szabadkai I, Brauswetter D, Bánhegyi P,
Varga A, Markó P, Boros S, Illyés E, Szántai-Kis C, Krekó M, Czudor Z, Őrfi L
Discovery and optimization of novel benzothiophene-3-carboxamides as highly potent inhibitors of Aurora kinases A and B
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 28:(19) pp. 3265-3270. (2018)
- Szabadkai I, Torka R, Garamvolgyi R, Baska F, Gyulavari P, Boros S, Illyes E, Choidas A, Ullrich A, Orfi L
Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors
JOURNAL OF MEDICINAL CHEMISTRY 61:(14) pp. 6277-6292. (2018)
- Czudor Z, Balogh M, Bánhegyi P, Boros S, Breza N, Dobos J, Fábián M, Horváth Z, Illyés E, Markó P, Sipos A,
Szántai-Kis C, Szokol B, Őrfi L
Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 28:(4) pp. 769-773. (2018)
- Singh V, Dhar N, Pató J, Kolly GS, Korduláková J, Forbak M, Evans JC, Székely R, Rybniker J, Palčeková Z, Zemanová J, Santi I, Signorino-Gelo F, Rodrigues L, Vocat A, Covarrubias AS, Rengifo MG, Johnsson K, Mowbray S, Buechler J, Delorme V, Brodin P, Knott GW, Aínsa JA, Warner DF, Kéri G, Mikušová K, McKinney JD, Cole ST, Mizrahi V, Hartkoorn RC
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria
MOLECULAR MICROBIOLOGY 103:(1) pp. 13-25. (2017)
- Booij TH, Klop MJD, Yan K, Szantai-Kis C, Szokol B, Orfi L, van de Water B, Keri G, Price LS
Development of a 3D Tissue Culture-Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases
JOURNAL OF BIOMOLECULAR SCREENING 21:(9) pp. 912-922. (2016)
- Garamvolgyi R, Dobos J, Sipos A, Boros S, Illyes E, Baska F, Kekesi L, Szabadkai I, Szantai-Kis C, Keri G, Orfi L
Design and synthesis of new imidazo[1,2-a]pyridine and imidazo [1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 108 pp. 623-643. (2015)
- Sipos A, Pato J, Szekely R, Hartkoorn RC, Kekesi L, Orfi L, Szantai-Kis C, Mikusova K, Svetlikova Z, Kordulakova J, Nagaraja V, Godbole AA, Bush N, Collin F, Maxwell A, Cole ST, Keri G
Lead selection and characterization of antitubercular compounds using the Nested Chemical Library
TUBERCULOSIS 95 pp. S200-S206. (2015)
- Rybniker J, Chen JM, Sala C, Hartkoorn RC, Vocat A, Benjak A, Boy-Rottger S, Zhang M, Szekely R, Greff Z, Orfi L, Szabadkai I, Pato J, Keri G, Cole ST
Anticytolytic screen identifies inhibitors of Mycobacterial virulence protein secretion
CELL HOST & MICROBE 16:(4) pp. 538-548. (2014)
- Pénzes K, Baumann C, Szabadkai I, Orfi L, Kéri G, Ullrich A, Torka R
Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells
CANCER BIOLOGY & THERAPY 15:(11) pp. 1571-1582. (2014)
- Torka R, Pénzes K, Gusenbauer S, Baumann C, Szabadkai I, Őrfi L, Kéri G, Ullrich A
Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy
NEOPLASIA 16:(4) pp. 301-318. (2014)
- Barman SA, Chen F, Su Y, Dimitropoulou C, Wang Y, Catravas JD, Han W, Orfi L, Szantai-Kis C, Keri G, Szabadkai I, Barabutis N, Rafikova O, Rafikov R, Black SM, Jonigk D, Giannis A, Asmis R, Stepp DW, Ramesh G, Fulton DJ
NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 34:(8) pp. 1704-1715. (2014)
- Baska F, Szabadkai I, Sipos A, Breza N, Szántai-Kis C, Kékesi L, Garamvölgyi R, Nemes Z, Baska F, Neumann L, Torka R, Ullrich A, Kéri G, Őrfi L
Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors
CURRENT MEDICINAL CHEMISTRY 21:(17) pp. 1938-1965. (2014)
- Szokol B, Gyulavári P, Kurkó I, Baska F, Szántai-Kis C, Greff Z, Őrfi Z, Peták I, Pénzes K, Torka R, Ullrich A, Őrfi L, Vántus T, Kéri G
Discovery and biological evaluation of novel dual EGFR/c-Met inhibitors
ACS MEDICINAL CHEMISTRY LETTERS 5:(4) pp. 298-303. (2014)
- Ho HK, Németh G, Ng YR, Pang E, Szántai-Kis C, Zsákai L, Breza N, Greff Z, Horváth Z, Pató J, Szabadkai I, Szokol B, Baska F, Őrfi L, Ullrich A, Kéri G, Chua BT
Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing.
CURRENT MEDICINAL CHEMISTRY 20:(10) pp. 1203-1217. (2013)
- Nemeth G, Varga Z, Greff Z, Bencze G, Sipos A, Szantai-Kis C, Baska F, Gyuris A, Kelemenics K, Szathmary Z, Minarovits J, Keri G, Orfi L
Novel, Selective CDK9 Inhibitors for the Treatment of HIV Infection.
CURRENT MEDICINAL CHEMISTRY 18: pp. 342-358. (2011)
- Borbely G, Szabadkai I, Horvath Z, Marko P, Varga Z, Breza N, Baska F, Vantus T, Huszar M, Geiszt M, Hunyady L, Buday L, Orfi L, Keri G
Small-Molecule Inhibitors of NADPH Oxidase 4.
JOURNAL OF MEDICINAL CHEMISTRY 53:(18) pp. 6758-6762. (2010)
- Petak I, Schwab R, Orfi L, Kopper L, Keri G
Integrating molecular diagnostics into anticancer drug discovery.
NATURE REVIEWS DRUG DISCOVERY 9:(7) pp. 523-535. (2010)
- Kirti Sharma, Christoph Weber, Michaela Bairlein, Zoltán Greff, György Kéri, Jürgen Cox, Jesper V Olsen, Henrik Daub
Proteomics strategy for quantitative protein interaction profiling in cell extracts.
NATURE METHODS 6:(10) pp. 741-744. (2009)
- Hegymegi-Barakonyi B, Eros D, Szantai-Kis C, Breza N, Banhegyi P, Szabo GV, Varkondi E, Petak I, Orfi L, Keri G
Tyrosine kinase inhibitors – Small molecular weight compounds inhibiting EGFR.
CURRENT OPINION IN MOLECULAR THERAPEUTICS 10:(3) pp. 308-321. (2009)
- Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai I, Daub H, Keri G, Ullrich A
AXL is a potential target for therapeutic intervention in breast cancer progression.
CANCER RESEARCH 68:(6) pp. 1905-1915. (2008)
- Wissing J, Jansch L, Nimtz M, Dieterich G, Hornberger R, Keri G, Wehland J, Daub H
Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry.
MOLECULAR & CELLULAR PROTEOMICS 6:(3) pp. 537-547. (2007)
- Kéri Gy, Orfi L, Eros D, Hegymegi-Barakonyi B, Szántai-Kis Cs, Horváth Z, Wáczek F, Marosfalvy J, Szabadkai I, Pató J, Greff Z, Hafenbradl D, Daub H, Müller G, Klebl B, Ullrich A
Signal Transduction Therapy with Rationally Designed Kinase Inhibitors.
CURRENT SIGNAL TRANSDUCTION THERAPY 1:(1) pp. 67-95. (2006)
- Keri G, Szekelyhidi Z, Banhegyi P, Varga Z, Hegymegi Barakonyi B, Szantai Kis C, Hafenbradl D, Klebl B, Muller G, Ullrich A, Eros D, Horvath Z, Greff Z, Marosfalvi J, Pato J, Szabadkai I, Szilagyi I, Szegedi Z, Varga I, Waczek F, Orfi L
Drug discovery in the kinase inhibitory field using the Nested Chemical Library (TM) technology.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES 3:(5) pp. 543-551. (2005)
- Godl K, Gruss O J, Eickhoff J, Wissing J, Blencke S, Weber M, Degen H, Brehmer D, Orfi L, Horvath Z, Keri G, Muller S, Cotten M, Ullrich A, Daub H
Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling.
CANCER RESEARCH 65:(15) pp. 6919-6926. (2005)
